Benchmark Upgrades Emergent BioSolutions to Buy, Announces $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Robert Wasserman upgrades Emergent BioSolutions (NYSE:EBS) from Hold to Buy and sets a $5 price target.

March 07, 2024 | 3:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Emergent BioSolutions upgraded by Benchmark from Hold to Buy with a $5 price target.
An upgrade from Hold to Buy typically indicates a positive outlook on the stock by the analyst, suggesting an expectation of outperformance in the near term. The setting of a price target provides a specific goal that can influence investor expectations and market sentiment towards the stock. Given the direct nature of this upgrade and price target announcement, it is likely to have a positive impact on the stock's price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100